JPH11507052A5 - - Google Patents

Info

Publication number
JPH11507052A5
JPH11507052A5 JP1997501345A JP50134597A JPH11507052A5 JP H11507052 A5 JPH11507052 A5 JP H11507052A5 JP 1997501345 A JP1997501345 A JP 1997501345A JP 50134597 A JP50134597 A JP 50134597A JP H11507052 A5 JPH11507052 A5 JP H11507052A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997501345A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11507052A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/008877 external-priority patent/WO1996040648A1/en
Publication of JPH11507052A publication Critical patent/JPH11507052A/ja
Publication of JPH11507052A5 publication Critical patent/JPH11507052A5/ja
Withdrawn legal-status Critical Current

Links

JP9501345A 1995-06-07 1996-06-04 キナゾリンおよび医薬組成物 Withdrawn JPH11507052A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48058995A 1995-06-07 1995-06-07
US08/480,589 1995-06-07
PCT/US1996/008877 WO1996040648A1 (en) 1995-06-07 1996-06-04 Quinazolines and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JPH11507052A JPH11507052A (ja) 1999-06-22
JPH11507052A5 true JPH11507052A5 (enExample) 2004-07-22

Family

ID=23908543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501345A Withdrawn JPH11507052A (ja) 1995-06-07 1996-06-04 キナゾリンおよび医薬組成物

Country Status (7)

Country Link
US (1) US6103728A (enExample)
EP (1) EP0832073B1 (enExample)
JP (1) JPH11507052A (enExample)
AU (1) AU5984296A (enExample)
CA (1) CA2222545A1 (enExample)
DE (1) DE69618587T2 (enExample)
WO (1) WO1996040648A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
TW321649B (enExample) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ510991A (en) 1997-03-05 2002-11-26 Sugen Inc Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
HUP0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US6800649B1 (en) 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
EP1510212A1 (en) * 1998-08-21 2005-03-02 Parker Hughes Institute Use of 4-substituted-quinazoline derivatives for producing therapeutic agents
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
CN1240688C (zh) 2000-04-07 2006-02-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
US7585866B2 (en) * 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1551824B1 (en) * 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
MX2008002207A (es) * 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
MX2008010668A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
MX2008010953A (es) * 2006-02-28 2008-09-08 Amgen Inc Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR20200003933A (ko) 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
FR3019819B1 (fr) * 2014-04-09 2018-03-23 Centre National De La Recherche Scientifique (Cnrs) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
EP3359526A4 (en) 2015-10-05 2019-04-03 The Trustees of Columbia University in the City of New York ACTIVATORS OF AUTOPHAGIC RIVER AND PHOSPHOLIPASE D AND PURIFICATION OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
MX2020012259A (es) 2018-05-18 2021-01-29 Novartis Ag Formas cristalinas de un inhibidor de tlr7/tlr8.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36256A (en) * 1862-08-19 Improvement in sewing-m ach ines
US3266990A (en) * 1963-09-24 1966-08-16 Warner Lambert Pharmaceutical Derivatives of quinazoline
US3800039A (en) * 1970-10-21 1974-03-26 Mead Johnson & Co Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
DE3920029C2 (de) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
ATE114661T1 (de) * 1990-04-02 1994-12-15 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06503095A (ja) * 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
EP0654024A1 (en) * 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
EP1238986B1 (en) * 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity

Similar Documents

Publication Publication Date Title
JP2001520615A5 (enExample)
JPH11506658A5 (enExample)
JP2000500445A5 (enExample)
JP2000500228A5 (enExample)
JP2000500440A5 (enExample)
JPH11506181A5 (enExample)
JP2000500327A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JPH11509838A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JPH11507052A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JPH11506104A5 (enExample)
JP2000500166A5 (enExample)
JP2000500125A5 (enExample)
JP2000500090A5 (enExample)
JP2000500257A5 (enExample)
JP2000500106A5 (enExample)